Thermal Burns

4
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

MediWound
MediWoundYAVNE, Israel
2 programs
2
NexoBridPhase 31 trial
NexoBridPhase 31 trial
Active Trials
NCT02148705Completed175Est. Aug 2020
NCT02278718Completed145Est. Dec 2022
NT
NeoMatrix TherapeuticsNY - Stony Brook
1 program
1
cP12Phase 21 trial
Active Trials
NCT06814717Recruiting6Est. Nov 2026
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
cP12Phase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MediWoundNexoBrid
MediWoundNexoBrid
NeoMatrix TherapeuticscP12

Clinical Trials (3)

Total enrollment: 326 patients across 3 trials

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

Start: May 2015Est. completion: Aug 2020175 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Start: May 2015Est. completion: Dec 2022145 patients
Phase 3Completed

A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns

Start: May 2025Est. completion: Nov 20266 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 326 patients
3 companies competing in this space